Ip Share Price. IPO - Stock Quote, Charts, Trade History, Share Chat, Financials. Ip Group Plc

Gold vs US Dollar

LSE company dividends information has been updated. You can find this is in the menu on any Quote page. ADVFN team.

Home
Investing
Stocks
UK
LSE
Ip Group Plc (IPO)
Ip Group Plc (IPO) Share Price

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Ip Group Plc	LSE:IPO	London	Ordinary Share	GB00B128J450	ORD 2P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	0.70	1.27%	56.00	1,101,366	16:35:05

Bid Price		Offer Price	High Price	Low Price	Open Price
56.00		56.20	56.50	55.30	55.30

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Finance Services	-299.80	-344.50	-	-	579.68

Last Trade Time	Trade Type	Trade Size	Trade Price	Currency
17:59:08	O	4,907	56.00	GBX

Related Shares
London Stock Exchange (LSEG), 3i (III), Mode Global (MODE), Agriterra Ld (AGTA)

Ip (IPO) Latest News

Ip News

Date	Time	Source	Headline
31/5/2023	14:34	UKREG	IP Group PLC Total Voting Rights
12/5/2023	13:27	UKREG	IP Group PLC Director Declaration
10/5/2023	12:11	UKREG	IP Group PLC Director/PDMR Shareholding
03/5/2023	10:56	UKREG	IP Group PLC Director Declaration
28/4/2023	15:21	UKREG	IP Group PLC Total Voting Rights
20/4/2023	17:00	UKREG	IP Group PLC Notice of AGM, Annual Report
18/4/2023	15:23	UKREG	IP Group PLC RSP & DBSP awards; Director/PDMR shareholding
15/3/2023	09:31	RNSNON	IP Group PLC Investor presentation
13/3/2023	12:18	ALNC	SUMMARY: London listings with exposure to Silicon Valley Bank
13/3/2023	09:00	UKREG	IP Group PLC Director/PDMR Shareholding

Ip Investors Ip Takeover Rumours

Ip (IPO) Discussions and Chat

Ip Forums and Chat

Date	Time	Title	Posts
30/5/2023	15:59	IP Group PLC	2,743
27/9/2021	08:52	ONT future steps.	4
23/12/2020	09:51	IP Group - commercialising university technology.	971
11/10/2012	07:43	::: The DIRECT LINE IPO :::	83
08/11/2010	07:59	IP 2 IPO, digging up value, from the boffins.	213

Add a New Thread

Ip (IPO) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
2023-06-02 16:59:29	56.00	4,907	2,747.92	O
2023-06-02 16:45:04	55.37	6,054	3,352.10	O
2023-06-02 16:45:04	55.93	8,000	4,474.48	O
2023-06-02 16:05:32	56.00	3,033	1,698.48	O
2023-06-02 15:57:01	56.00	625	350.02	O

View all Ip trades in real-time

Ip (IPO) Top Chat Posts

Top Posts
Posted at 19/5/2023 07:33 by palisz Like any vote, it only works if people make their voices heard. Nice update this morning from ONT...a pop there may help since its value is nearly 40% of IPO price. Read Full Thread Follow Reply
Posted at 12/5/2023 07:13 by boystown From Money Week today: "IP Group (LSE: IPO) is a UK mid-cap that is discounting too much bad news. The company helps fund innovative technologies from the UK’s leading universities. Venture funding is an area under pressure owing to rising interest rates. The group’s recent estimated net asset value of 130p per share will come under some pressure. However, we note that some of the investments, such as Featurespace, a software group using artificial intelligence (AI) to combat financial crime, are highly promising and should raise money successfully. Today’s share price of 60p is unrealistically pessimistic and we believe that IP Group will soon repeat its 2020 recovery, when the shares rallied from 50p to 150p." Read Full Thread Follow Reply
Posted at 05/5/2023 19:57 by bamboo2 I have emailed the co about the P/f updates on the website. There are plans to introduce it back. I am unsure why they made the changes, as it obviously cost £££'s, but is less functional than it was previously. We do have pictures of the management looking like they just won the lottery. I guess in a way they have, given that their bonuses are based on NAV, rather than market based share price. Read Full Thread Follow Reply
Posted at 27/4/2023 17:19 by bamboo2 I checked again this afternoon, looking back over several reports, and realised an error in my early maths. These are the actual figures, so Imperial are still holding just over 30m shares, and they are using the closing price on the last day of the reporting month. Will correct the above post. Jan 23 £18,808,814 31/01/23 share price £0.61 £18,808,814/.61 = 30,834,121.3115 sh Oct 22 £18,207,055 31/10/22 share price £0.59 £18,207,055/.59 = 30,859,415.2542 sh Jul 22 £26,616,246 31/07/22 share price £0.86 £26,616,246/.86 = 30,949,123.2558 sh Read Full Thread Follow Reply
Posted at 22/4/2023 18:25 by bamboo2 FOR RELEASE ON 20 April 2023 IP Group - 2022 Annual Report; Notice of Annual General Meeting ("AGM") IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), which invests in breakthrough science and innovation companies with the potential to create a better future for all, announces that it has published its Annual Report and Accounts for the year ended 31 December 2022. In compliance with Listing Rule 9.6.3, a copy of the following documents will shortly be available for inspection at www.fca.org.uk/markets/primary-markets/regulatory-disclosures/national-storage-mechanism . - Annual Report and Accounts for the year ended 31 December 2022 ("2022 ARA"); and - Notice of 2023 Annual General Meeting ("2023 AGM Notice"). Printed copies of the 2022 ARA and the 2023 AGM Notice, together with the Form of Proxy for use in connection with the 2023 AGM, have been posted to shareholders who have requested hard copies. An electronic copy of the 2022 ARA is available on the Investor Relations section of the IP Group website at www.ipgroupplc.com/investor-relations . A copy of the 2023 AGM Notice is also available electronically on the IP Group website at hxxps://www.ipgroupplc.com/investors/shareholder-information/agm . The Dividend Mandate Form is also available on the Company's website at hxxps://www.ipgroupplc.com/investors/shareholder-information/dividend . The 2023 AGM will be held at 11.00am on 15 June 2023 at the Company's offices at 3 Pancras Square, King's Cross, London, N1C 4AG, as further set out in the 2023 AGM Notice. To ensure that shareholders can also follow the proceedings of the AGM virtually, the Company will provide access online via the Investor Meet Company platform. However, please note that shareholders will not be able to vote online at the AGM via the platform and are therefore requested to submit their votes via proxy, as early as possible, as further detailed in the 2023 AGM Notice. The Company will also hold an investor event immediately before the AGM at which an update on the Group will be provided and shareholders will be able to ask questions of the Board. Any shareholder attending the AGM in person will be able to attend the shareholder event (and vice versa). The shareholder event will take place from 9.30am-10.30am (with refreshments available from 9.00am) and will also be streamed live to those who wish to attend virtually. Whilst live questions will be accepted on the day, in order to facilitate the smooth running of the shareholder event and AGM, shareholders are encouraged to submit any questions for the Board to consider via the Investor Meet Company Platform up until 9am the day before the AGM. Shareholders can also submit questions in advance by email to cosec@ipgroupplc.com up to 48 hours prior to the time of the AGM. Shareholders that wish to attend the shareholder event and AGM remotely should register in advance by using the following link: Https://www.investormeetcompany.com/ip-group-plc/register-investor . Read Full Thread Follow Reply
Posted at 10/3/2023 12:50 by brucie5 Yes, agreed, and whole market down today. My folio which carries considerable value/income bias currently down 2.3%, so IPO (3.1%) not an outlier by much. 55p hit, and I think 50p may indeed follow. But question is, what then. Or, what level is so absurd that the equivalent of PE decides to correct the anomaly? I understand that PE is not likely; but some cherry picking of distressed asset prices? Anyone recall Shell at £9 in late 2020? Why did we all buy? At some point pension funds need to consider where the growth is going to come from tomorrow, never mind the dividends today. On a ten year view, and assuming continued progress with just the ten top holdings, where is IPO share price? Read Full Thread Follow Reply
Posted at 08/3/2023 07:23 by bamboo2 FOR RELEASE ON 8 March 2023 ("IP Group" or "the Group" or "the Company") IP Group plc Annual Results Release Group well financed and focused on delivering returns for stakeholders; resilient portfolio, well-funded & aligned to three world-changing themes IP Group plc (LSE: IPO), which invests in breakthrough science and innovation companies with the potential to create a better future for all, today announces its annual financial results for the year ended 31 December 2022. 2022 highlights Significant progress in key themes & companies -- Regenerative future (Cleantech): Strong return in the period delivered by uplifts at First Light Fusion, which achieved world-first fusion result with 'projectile fusion', externally validated by the UK Atomic Energy Authority; and Oxbotica which completed a $140m Series C financing round at significant uplift -- Healthier future (Life Sciences): Istesso commenced Phase 2b trial for its lead drug MBS2320 in rheumatoid arthritis; MBS2320 granted Fast Track designation by the US FDA for the treatment of patients with idiopathic pulmonary fibrosis ("IPF") & also designated it an orphan drug for the treatment of IPF -- Tech-enriched future (Deeptech) : Featurespace, Garrison, SaltPay, Ultraleap all posted double-digit revenue growth; sale of Re:Infer to global leader UiPath, delivering IRR of 29% Delivering evolved strategy -- Deeper thematic focus which included the launch of dedicated cleantech platform Kiko Ventures -- Third-party capital funds under management increased to GBP697m vs GBP575m in 2021, in line with long-term strategy -- Increased impact, together with Parkwalk, IP Group is one of the largest investors in university and other research-based companies in the world; the most prolific investor in deeptech companies in the UK and the second most prolific in Europe Well financed & resilient portfolio -- Strong balance sheet and liquidity to support new and follow-on investment in the portfolio with gross cash and deposits at 31 December 2022 of GBP241.5m (2021: GBP321.9m); total potential liquidity (including quoted shares and undrawn debt) of over GBP500m -- Loss in the period of GBP344.5m (2021: profit of GBP449.3m). Driven primarily by a reduction in the value of our public companies of GBP428.5m and in the value of ONT in particular, which reduced by GBP369.7m -- Portfolio companies well-funded; total funds raised by portfolio GBP1.0bn (2021: GBP2.4bn) -- Private portfolio company valuations remained robust with 90% of our portfolio funding rounds in 2022 taking place at or above previous funding round valuations -- Recommended final dividend of 0.76p per share to give a total 1.26p for FY22 (interim dividend of 0.50p per share; 2021 total dividend of 1.2p per share), completion of GBP35m share buyback; GBP20.3m total capital returned to shareholders in the year Post period-end update -- Appointment of Anita Kidgell, Head of Corporate Strategy at GSK plc, as independent Non-executive Director -- The fair value of the Group's holdings in listed companies experienced a net fair value decrease of GBP26.2m in the period since 31 December, including ONT decreasing by GBP28.3m. Summary financials FY 2022 FY 2021 ----------------------------- --------------------- --------------------- Net Asset Value (NAV) GBP1,376.1m; 132.9pps GBP1,738.1m; 167.0pps ----------------------------- --------------------- --------------------- Loss/profit Loss of (GBP344.5m) Profit of GBP449.3m ----------------------------- --------------------- --------------------- Loss/profit excluding ONT (i) Profit of GBP25.2m Profit of GBP202.1m ----------------------------- --------------------- --------------------- Total portfolio (i) GBP1,258.5m GBP1,507.5m ----------------------------- --------------------- --------------------- Net portfolio loss/profit (i) GBP309.1m loss GBP499.2m gain ----------------------------- --------------------- --------------------- Gross cash and deposits (i) GBP241.5m GBP321.9m ----------------------------- --------------------- --------------------- Realisations GBP28.1m GBP213.9m ----------------------------- --------------------- --------------------- Portfolio investment (i) GBP93.5m GBP106.8m ----------------------------- --------------------- --------------------- Total dividend(ii) 1.26pps 1.20pps ----------------------------- --------------------- --------------------- (i) Note 29 details the Alternative Performance Measures ("APM") (ii) Total dividend for 2022 subject to approval of final dividend of 0.76pps at the Group's 2023 AGM Greg Smith, Chief Executive of IP Group, said: "We have continued to see strong commercial progress and interest in our portfolio this year despite the economic headwinds and prevailing geopolitical environment. IP Group is well financed and our strong balance sheet allows us to continue to capitalise on opportunities in the UK and internationally. Our portfolio is also well funded which, together with our decades of experience in supporting fast growing companies, ensures our companies are well-placed to navigate this environment. While the share prices of our publicly listed companies and that of the Group have come under pressure, we remain focussed on generating returns for all stakeholders and are confident that our high-quality portfolio will generate significant value over time." Webinar IP Group will host a webinar for analysts and investors today, 8 March, at 10:00am. For more details or to register as a participant please visit Https://www.investormeetcompany.com/ip-group-plc/register-investor. Https://www.ipgroupplc.com/~/media/Files/I/IPGroup-PLC/press-releases/IP-Group-2022%20RNS-vF-002.pdf Read Full Thread Follow Reply
Posted at 12/12/2022 19:32 by bamboo2 I think one of the issues is the obvious disconnect between NAV, and the share price. The fact the management give themselves free shares based on the NAV performance, while the rest of us have only the share price/dividend payments to reflect upon is clearly unfair. As in previous years, I will continue to raise this matter during management Q&A sessions, and suggest others do the same. Read Full Thread Follow Reply
Posted at 30/8/2022 08:48 by oakville 30 August 2022 RECOMMED CASH ACQUISITION of Diurnal Group plc ("Diurnal") by Neurocrine Biosciences, Inc. ("Neurocrine") to be implemented by means of a Scheme of Arrangement under Part 26 of the Companies Act 2006 Summary -- The boards of Neurocrine and Diurnal are pleased to announce that they have reached agreement on the terms of a recommended cash acquisition pursuant to which Neurocrine shall acquire the entire issued and to be issued ordinary share capital of Diurnal (the "Acquisition"). The Acquisition is to be effected by means of a scheme of arrangement under Part 26 of the Companies Act. -- The Acquisition values the entire issued and to be issued ordinary share capital of Diurnal at approximately GBP48.3 million. -- Under the terms of the Acquisition, Diurnal Shareholders shall be entitled to receive 27.5 pence in cash for each Diurnal Share, representing a premium of approximately: o 144 per cent. to the Closing Price per Diurnal Share of 11.25 pence on 26 August 2022 (being the last Business Day prior to this announcement, the "Latest Practicable Date"); and o 151 per cent. to the volume weighted average Closing Price of 10.93 pence per Diurnal Share for the three months ended on the Latest Practicable Date . -- If, on or after the date of this announcement and on or prior to the Effective Date, any dividend, distribution, or other return of value is declared, made, or paid or becomes payable by Diurnal, the Acquisition Price shall be reduced accordingly. In such circumstances, Diurnal Shareholders shall be entitled to retain any such dividend, distribution, or other return of value declared, made, or paid. -- The Acquisition is conditional on, amongst other things, the approval of Diurnal Shareholders. Information on Neurocrine -- Neurocrine is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. Neurocrine is dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Neurocrine's portfolio includes FDA-approved treatments for tardive dyskinesia (TD), Parkinson's disease, endometriosis and uterine fibroids, and a diversified portfolio of investigational therapies with the potential to address unmet clinical needs of patients worldwide living with neurological, endocrine and psychiatric disorders. Neurocrine has a workforce of approximately 1,200 employees, and is headquartered in San Diego, California. -- For the year ended 31 December 2021, Neurocrine reported net product sales of $1.09 billion (c. GBP0.9 billion) and net income of $89.6 million (c.GBP75.3 million). As at the Latest Practicable Date, Neurocrine had a market capitalisation of $10.0 billion (c.GBP8.4 billion). Information on Diurnal -- Diurnal is a European specialty pharmaceutical group targeting patient needs in chronic endocrine (hormonal) diseases. Diurnal aims to develop and commercialise products to solve patient needs in endocrine diseases, primarily those that result from a deficiency of cortisol and testosterone, typically where there is either no licensed medicine or where current treatment does not sufficiently address patients' needs. Diurnal's portfolio includes approved treatments for paediatric adrenal insufficiency (AI) and congenital adrenal hyperplasia (CAH). Diurnal has a workforce of 33 employees, and is headquartered in Cardiff, UK. -- For the six months ended 31 December 2021, Diurnal reported unaudited net product sales (including royalties) of GBP2.13 million and a net loss of GBP7.95 million. As at the Latest Practicable Date, Diurnal had a market capitalisation of GBP19.1 million. Unaudited net product sales (including royalties) for the twelve months to 30 June 2022 were GBP4.62 million. Diurnal recommendation -- The Diurnal Directors, who have been so advised by Panmure Gordon as to the financial terms of the Acquisition, consider the terms of the Acquisition to be fair and reasonable. In providing its advice to the Diurnal Directors, Panmure Gordon has taken into account the commercial assessments of the Diurnal Directors. Panmure Gordon is providing independent financial advice to the Diurnal Directors for the purposes of Rule 3 of the Code. -- Accordingly, the Diurnal Directors intend to recommend unanimously that Diurnal Shareholders vote in favour of the Scheme at the Court Meeting and the resolution to be proposed at the General Meeting (or, in the event that the Acquisition is implemented by way of a Takeover Offer, to accept or procure acceptance of the Takeover Offer), as those Diurnal Directors who hold Diurnal Shares have irrevocably undertaken to do in respect of their own beneficial holdings of 3,030,867 Diurnal Shares representing, in aggregate, approximately 1.8 per cent. of the ordinary share capital of Diurnal in issue on the Latest Practicable Date. -- Neurocrine has also received an irrevocable undertaking to vote in favour of the Scheme at the Court Meeting and the resolutions to be proposed at the General Meeting (or, in the event that the Acquisition is implemented by way of a Takeover Offer, to accept or procure acceptance of the Takeover Offer) from IP Group in respect of a total of 49,900,285 Diurnal Shares, representing, in aggregate, approximately 29.3 per cent. of the ordinary share capital of Diurnal in issue on the Latest Practicable Date. -- In addition, Neurocrine has also received an irrevocable undertaking to vote in favour of the Scheme at the Court Meeting and the resolutions to be proposed at the General Meeting (or, in the event that the Acquisition is implemented by way of a Takeover Offer, to accept or procure acceptance of the Takeover Offer) from (i) Development Bank of Wales in respect of a total of 11,534,888 Diurnal Shares, representing, in aggregate, approximately 6.8 per cent. of the ordinary share capital of Diurnal in issue on the Latest Practicable Date and (ii) Polar Capital Holdings plc in respect of a total of 20,000,000 Diurnal Shares, representing, in aggregate, approximately 11.8 per cent. of the ordinary share capital of Diurnal in issue on the Latest Practicable Date. -- Neurocrine has therefore received irrevocable undertakings in respect of a total of 84,466,040 Diurnal Shares representing, in aggregate, approximately 49.7 per cent. of the ordinary share capital of Diurnal in issue on the Latest Practicable Date. -- Further details of these irrevocable undertakings are set out in Appendix 3 to this announcement. -- In addition to the irrevocable undertakings, Neurocrine has received a letter of intent from Amati Global Investors in respect of 8,786,429 Diurnal Shares, representing, in aggregate, approximately 5.2 per cent. of the ordinary share capital of Diurnal in issue on the Latest Practicable Date. -- In total, Neurocrine has received irrevocable undertakings and a letter of intent in respect of a total of 93,252,469 Diurnal Shares representing, in aggregate, approximately 54.8 per cent. of the ordinary share capital of Diurnal in issue on the Latest Practicable Date. Timetable and Conditions -- The Acquisition shall be put to Scheme Shareholders at the Court Meeting. In order to become effective, the Scheme must be approved by a majority in number of the Scheme Shareholders voting at the Court Meeting, either in person or by proxy, representing at least 75 per cent. in value of the Scheme Shares voted. In addition, the implementation of the Scheme must also be approved at the General Meeting by Diurnal Shareholders representing at least 75 per cent. of votes cast at the General Meeting. -- The Conditions to the Acquisition are set out in Appendix 1 to this announcement, along with certain other terms; the full terms and conditions will be provided in the Scheme Document. -- The Scheme Document, containing further information about the Acquisition and notices of the Court Meeting and the General Meeting shall be published as soon as practicable and, in any event, within 28 days of this announcement (or such later time as the Panel agrees). -- The Acquisition is currently expected to complete during late October or early November 2022, subject to satisfaction or (where applicable) waiver of the Conditions. An expected timetable of key events relating to the Acquisition will be provided in the Scheme Document. Commenting on the Acquisition, Anders Härfstrand, Non-Executive Chairman of Diurnal, said: " The Board of Diurnal is delighted to announce this recommended offer for Diurnal. Diurnal and Neurocrine are highly complementary businesses, and we believe that Neurocrine's financial and operational resources will substantially accelerate the development of a leading franchise in diseases of cortisol deficiency, benefiting physicians and patients globally. We believe that the Acquisition is compelling for Diurnal's shareholders given the risks associated with achieving Diurnal's vision of creating a profitable business, in particular the ongoing commercial roll out of Diurnal's products in Europe and the execution of key clinical studies, in addition to the substantial shareholder dilution that is likely to result from accessing the capital required to deliver this vision." Commenting on the Acquisition, Kyle Gano, Chief Business Development and Strategy Officer of Neurocrine, said: "We have followed Diurnal for several years and have a high regard for its people. We see a good strategic fit that offers benefits for both companies' stakeholders and the physician and patient communities we both serve." This summary should be read in conjunction with the full text of this announcement (including the Appendices). The Acquisition shall be subject to the Conditions and further terms set out in Appendix 1 to this announcement and to the full terms and conditions which shall be set out in the Scheme Document. Appendix 2 to this announcement contains the sources of information and bases of calculations of certain information contained in this announcement, Appendix 3 to this announcement contains a summary of the irrevocable undertakings received in relation to this Acquisition and Appendix 4 to this announcement contains definitions of certain expressions used in this summary and in this announcement. Read Full Thread Follow Reply
Posted at 18/4/2022 10:37 by pugugly PO & b2 - Agree your reasoning, especially re cash but still feel that unless the American love affair with tech recovers significantly IPO share price will not recover/ Very similar to recent chart pattern to SMT. Also possibly many PI's still suffering from the lessons of Woodford Patient Capital. OK I fully appreciate that IPO management far more competent that the Woodford crew but IPO could well get tarred with the same brush. Read Full Thread Follow Reply

Ip share price data is direct from the London Stock Exchange

Your Recent History

LSE

IPO

Ip

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea

V: D: 20230602 23:16:13